Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WW domain-containing transcription regulator protein 1 (WWTR1), commonly known as TAZ (transcriptional coactivator with PDZ-binding motif), is a key downstream effector of the Hippo signaling pathway. TAZ acts as a transcriptional coactivator that shuttles between the cytoplasm and the nucleus, where it binds to TEAD transcription factors to drive the expression of genes involved in cell proliferation, survival, and stem cell self-renewal. Under normal physiological conditions, TAZ is regulated by upstream Hippo pathway kinases (such as MST1/2 and LATS1/2) which phosphorylate TAZ, leading to its cytoplasmic retention and proteasomal degradation. However, in many human cancers, dysregulation of the Hippo pathway or mechanical cues from a stiff extracellular matrix lead to aberrant nuclear accumulation of TAZ, promoting tumor growth, metastasis, epithelial-mesenchymal transition (EMT), and drug resistance.\n\nConsequently, TAZ has emerged as an attractive therapeutic target in oncology, particularly for Hippo-mutant tumors like malignant pleural mesothelioma. Therapeutic strategies include direct disruptors of the YAP/TAZ-TEAD protein-protein interaction (such as IAG933) and small-molecule inhibitors of TEAD palmitoylation (such as VT3989 and IK-930) that indirectly prevent TAZ-mediated transcription. However, systemic inhibition of TAZ poses significant safety challenges, most notably renal toxicity (such as podocyte damage and proteinuria) and impaired tissue regeneration, necessitating carefully designed dosing regimens.
Disruption of the YAP/TAZ-TEAD protein-protein interaction, inhibition of TEAD auto-palmitoylation, and prevention of TAZ nuclear translocation.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WW domain-containing transcription regulator protein 1 (TAZ).